Table 4. Resistance Studies.
| Inhibitor Name | Lifecycle Stage | Genotype Selectivitya | Fold Resistanceb | HCV Proteins | Amino Acid Substitutions | |
| Control Inhibitors | EIe | Entry | 1a/1b | 45c (3)d | E2 | V336G |
| LY411575 | Assembly | 1a/1b/2a | None | - | - | |
| Screen Hits | Inh-2 | Entry | 1a | >10 (3) | E1 | L67F |
| >10 (3) | E2 | W333L | ||||
| Inh-4 | Early | 1a/1b/2a | None | - | - | |
| Inh-6 | Replication | 2a | 30 (4) | NS5A | F28L, L31M, F169L | |
| 100 (4) | NS5A | L31M, S38T, Q123R | ||||
| Inh-7 | Replication | 2a | >10 (4) | NS4B | G60S | |
| Inh-17 | Late | 1a/1b/2a | None | - | - |
a
Genotype coverage using gt 1a, 1b and 2a chimeric HCVcc.
b
Virus cultured at 5× EC50 up to 10 weeks or until resistance observed.
c
Mean fold resistance from 3 independent experiment.
d
Time point (weeks) when resistance was observed.
e
Baldick et al. 2009.